世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のヘルスケアCMO市場。タイプ別(医薬品、医療機器)、地域別(北米、欧州、アジア太平洋、ROW)、COVID-19の影響を受けたサイズと傾向の分析、2027年までの予測


Global Healthcare CMO Market: Analysis By Type (Pharmaceutical and Medical Device), By Region (North America, Europe, Asia Pacific, ROW), Size and Trends with Impact of COVID-19 and Forecast up to 2027

世界のヘルスケアCMO市場は、2021年に1,159億米ドルとなり、2027年には2,302億4千万米ドルに成長すると予測されています。ヘルスケアCMO(ヘルスケア受託製造機関)とは、法的な契約に基づいて一定期間、医薬品開... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Daedal Research
デダルリサーチ
2022年10月19日 US$2,250
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
140 英語

 

サマリー

世界のヘルスケアCMO市場は、2021年に1,159億米ドルとなり、2027年には2,302億4千万米ドルに成長すると予測されています。ヘルスケアCMO(ヘルスケア受託製造機関)とは、法的な契約に基づいて一定期間、医薬品開発・製造などの包括的なサービスを提供する企業です。

ヘルスケア業界において、CMO(Contract Manufacturing Organization)は、製薬会社や病院などにサービスを提供します。プレフォーミュレーション、製剤開発、安定性試験、製法開発、前臨床試験および第I相臨床試験用資材、後期臨床試験用資材などのサービスが提供されます。世界のヘルスケアCMO市場は、2022年から2027年の予測期間において、12.12%のCAGRで成長することが決定しています。

市場セグメンテーション分析。

タイプ別。本レポートでは、タイプ別に2つのセグメントを識別しています。医薬品と医療機器である。医薬品CMOセグメントは、さらにサービスに基づいて2つのセグメントに分けられます。医薬品原薬(API)およびその他です。デバイス製造分野は、予測期間中、CAGR13%と最も速い速度で市場が成長すると予想されます。これは、社内製造施設の不足と複雑さにより、デバイス製造のアウトソーシングが増加しているためです。CMOは、サプライチェーンマネジメントのほか、品質管理システム、組み立て、統合、テストの能力を備えており、経験豊富なメーカーは、予測期間中に医療機関と迅速に提携できる体制を整えています。

地域別。本レポートでは、世界のヘルスケアCMO市場を4つの地域に分類しています。北米、欧州、アジア太平洋地域、ROWです。北米は、2021年の世界市場の37%以上の最大シェアを占めています。北米の市場は、同地域が創薬と製造のアウトソーシングに重点を置くようになったことが要因となっています。同地域では、薬剤の発見と開発につながる疾患メカニズムの科学的探求の利用が増加しています。前臨床試験は、医薬品の研究において重要な段階です。この段階では、医薬品が臨床試験に耐えうるかどうかを判断するために、いくつかの試験が実施されます。

アジア太平洋地域は、予測期間中に著しく高い成長率を示すと予測されています。この地域のさまざまな国の政府は、COVID-19の大流行に対抗するために、人工呼吸器などの生命維持装置の生産を加速させるために、地元のCMOと大規模な契約を結んでいます。そのため、人工呼吸器などの医療機器は、患者の生命維持のために、より重要なものとなっています。したがって、当局とCMOの協力は人工呼吸器の増産につながり、予測期間中の市場成長を後押しするものと思われます。

市場ダイナミクス

成長の原動力。市場拡大の主な要因の1つは、ハーブ製品への傾倒が高まっていることです。近年、消費者は自然/ハーブの美容製品を強く好む傾向にあるため、化粧品やパーソナルケア製品にハーブの成分が使用されることが多くなっています。また、消費者のニーズの高まりや持続可能な原材料の確保を背景に、合成化学物質から天然成分への切り替えに力を入れる企業も増えています。このような継続的な需要に対応するため、企業は製造プロセスを第三者機関であるCMOに移行しており、これが化粧品およびパーソナルケア分野におけるCMOの成長を助け、市場の成長を後押ししています。その他の重要な成長要因としては、高齢者人口の急増、医療費の増加、慢性疾患の蔓延、ジェネリック医薬品需要の増加、原薬の需要増などが挙げられます。

課題しかし、急速な技術進歩や特許・著作権・商標・企業秘密への依存など、いくつかの課題が市場の成長を阻害しています。業界のプレーヤーは、ノウハウ、企業秘密、特許、著作権、商標、その他の知的財産権に関する法律、秘密保持契約、その他の契約条項、技術的手段を組み合わせて、企業の提供物や無形資産の多くを保護しています。これらの財産権は、継続的な事業活動にとって重要なものです。当社の一部の製品にかかる独占的権利は特許により保護されていますが、その一部は近い将来失効する可能性があります。特許が失効した場合、独占権の喪失により、企業は第三者との競争を余儀なくされる可能性があり、その結果、売上及び収益性に悪影響を及ぼすと同時に、業界の成長も阻害される可能性があります。

動向。人工知能技術の役割のエスカレートと高度な呼吸器機器の進化により、予測期間中、市場は速いペースで成長すると予測されます。ヘルスケアの人工知能(AI)は、反復作業、治療計画の設計、投薬管理、創薬などを支援することで変貌を遂げました。また、データの収集、保存、正規化により、ヘルスケアデータ管理にも効果的に利用できる。受託製造企業は、AIやその他の技術革新を取り入れることで、より費用対効果が高くなり、生産時間を短縮しています。さらに、医薬品CMOは、より優れたリスク検出を促進し、ひいては医薬品の品質と安全性を向上させるために、常にAI技術の開発に取り組んでいます。

COVID-19の影響分析および今後の方向性。

COVID-19のパンデミックは、世界中で公衆衛生上の大きな懸念となっています。しかし、CMOが提供するバイオ医薬品サービスの増加により、市場にはポジティブな需要ショックが発生しました。CMOは、大量生産に対応するための設備投資や買収を進めています。このパンデミックは、継続的な供給のために、より高い生産量を確保するための設備やバイオプロセシング装置が飛躍的に成長する時代であることを証明しています。

ヘルスケアCMO市場におけるワクチンの開発・製造活動は、主にCOVID-19の大流行に対する業界の対応により、昨年から活発化しています。このような拡大は、今後数年間も続くと予想されます。CMOは、サプライチェーンの課題に対応するため、能力およびリソースへの投資を行っています。CMO業界では、モジュールの建設や拡張、最先端技術への投資、プロセスの集約化戦略が増加しています。さらに、多くのCMOが[メッセンジャーRNA]mRNAや細胞・遺伝子治療などの新しいモダリティで能力を拡大しており、これがポストCOVID期間中の市場の成長を後押しすることになるでしょう。

競合他社の状況

世界のヘルスケアCMO市場は中規模にまとまっています。戦略的提携もまた、競争上の優位性を得るために用いられる一般的な戦略である。例えば、キャタレントは2020年2月、Zumutor Biologics Inc.と、固形腫瘍を治療するZumutorのZM008を製造する契約を締結した。

世界のヘルスケアCMO市場の主なプレイヤーは以下の通りです。

キャタレント・ファーマ・ソリューションズ(Catalent Pharma Solutions, Inc.
サムスンバイオロジクス Co.Ltd.
オーロビンド ファーマ リミテッド
ベーリンガーインゲルハイムGmbH
インテージ・ホールディングス株式会社
ピラマル・エンタープライズ・リミテッド
ロンザグループAG
Koninklijke DSM N.V. (Royal DSM)
サーモフィッシャーサイエンティフィック
レシプファームAB
ファレバグループ
シンビオシス ファーマシューティカル サービス

ヘルスケアCMO市場の主要プレイヤーは、詳細な競争環境を提供し、必要な承認を得て新規製品を発売することに注力しています。研究開発の必要性は継続的にあり、市場プレイヤーの間では依然として重要な戦略となっています。これらの主要なプレーヤーは、今後数年間で市場の見通しを拡大するために、斬新な戦略を実施しています。2021年4月、サーモフィッシャーサイエンティフィックは、バイオテクノロジー業界への医薬品製造および臨床研究サービスのグローバルプロバイダーであるPPD社の買収を発表した。これにより、同社の製造能力と顧客基盤の拡大により、市場での地位が向上する。2021年5月、Samsung BiologicsとModerna Inc.は、ModernaのCOVID-19ワクチンの充填・仕上げサービスを提供するための提携を発表した。



ページTOPに戻る


目次

1. Executive Summary

2. Introduction

2.1 Healthcare Contract Manufacturing Organization (CMO): An Overview
2.1.1 Benefits Of Healthcare CMOs

2.2 Healthcare CMO Segmentation: An Overview
2.2.1 Healthcare CMO Segmentation

3. Global Market Analysis

3.1 Global Healthcare Contract Manufacturing Organization (CMO) Market: An Analysis

3.1.1 Global Healthcare CMO Market: An Overview
3.1.2 Global Healthcare Contract Manufacturing Organization (CMO) Market by Value
3.1.3 Global Healthcare Contract Manufacturing Organization (CMO) Market by Type (Pharmaceutical and Medical Device)
3.1.4 Global Healthcare Contract Manufacturing Organization (CMO) Market by Region (North America, Europe, Asia Pacific, and rest of the World (ROW)

3.2 Global Healthcare CMO Market: Type Analysis

3.2.1 Global Healthcare CMO Market by Type: An Overview
3.2.2 Global Pharmaceutical CMO Market by Value
3.2.3 Global Pharmaceutical CMO Market by Service (Active Pharmaceutical Ingredients (API) and Others)
3.2.3 Global Pharmaceutical CMO Market by Service: An Overview
3.2.4 Global Active Pharmaceutical Ingredients (API) CMO Market by Value
3.2.5 Global Other Pharmaceuticals CMO Market by Value
3.2.6 Global Medical Devices CMO Market by Value

4. Regional Market Analysis

4.1 North America Healthcare CMO Market: An Analysis

4.1.1 North America Healthcare CMO Market: An Overview
4.1.2 North America Healthcare CMO Market by Value
4.1.3 North America Healthcare CMO Market by Region (The US, Canada and Mexico)
4.1.4 The US Healthcare CMO Market by Value
4.1.5 The US Healthcare CMO Market by Type (Pharmaceutical and Medical Device)
4.1.6 The US Pharmaceutical Healthcare CMO Market by Value
4.1.7 The US Medical Devices Healthcare CMO Market by Value
4.1.8 Canada Healthcare CMO Market by Value
4.1.9 Mexico Healthcare CMO Market by Value

4.2 Europe Healthcare CMO Market: An Analysis

4.2.1 Europe Healthcare CMO Market: An Overview
4.2.2 Europe Healthcare CMO Market by Value
4.2.3 Europe Healthcare CMO Market by Region (Germany, The UK, France, Italy, Spain, and Rest of the Europe)
4.2.4 Germany Healthcare CMO Market by Value
4.2.5 The UK Healthcare CMO Market by Value
4.2.6 France Healthcare CMO Market by Value
4.2.7 Italy Healthcare CMO Market by Value
4.2.8 Spain Healthcare CMO Market by Value
4.2.9 Rest of Europe Healthcare CMO Market by Value

4.3 Asia Pacific Healthcare CMO Market: An Analysis

4.3.1 Asia Pacific Healthcare CMO Market: An Overview
4.3.2 Asia Pacific Healthcare CMO Market by Value
4.3.3 Asia Pacific Healthcare CMO Market by Region (China, Japan, India, South Korea, and Rest of the Asia Pacific)
4.3.4 China Healthcare CMO Market by Value
4.3.5 Japan Healthcare CMO Market by Value
4.3.6 India Healthcare CMO Market by Value
4.3.7 South Korea Healthcare CMO Market by Value
4.3.8 Rest of Asia Pacific Healthcare CMO Market by Value

4.4 Rest of World Healthcare CMO Market: An Analysis

4.4.1 Rest of World Healthcare CMO Market: An Overview
4.4.2 Rest of World Healthcare CMO Market by Value

5. Impact of Covid-19

5.1 Surge in Contracts to CDMOs
5.2 Supply Chain Issues Amidst Surge in Demand for CDMOs
5.3 Preparedness Measures in the Event of Supply Chain Disruption
5.4 Post-COVID Scenario

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Surging Geriatric Population
6.1.2 Rising Healthcare Expenditure
6.1.3 Increasing Spread of Chronic Diseases
6.1.4 Escalating Demand for Generic Drugs
6.1.5 Growing Inclination Towards Herbal Products
6.1.6 Increasing Demand for Active Pharmaceutical Ingredient (API)

6.2 Challenges
6.2.1 Rapid Technological Advancements
6.2.2 Dependent on Patents, Copyrights, Trademarks and Trade Secrets

6.3 Market Trends
6.3.1 Escalating Role of Artificial Intelligence Technology
6.3.2 Evolution of Advanced Respiratory Equipment

7. Competitive Landscape

7.1 Global Healthcare CMO Market Players Financial Comparison
7.2 Global Healthcare CMO Market Players by Research & Development (R&D) Expenses

8. Company Profiles

8.1 Catalent Pharma Solutions Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategy

8.2 Samsung Biologics Co. Ltd.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategy

8.3 Aurobindo Pharma Limited
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategy

8.4 Boehringher Ingelheim
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategy

8.5 Integer Holdings Corporation
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy

8.6 Piramal Enterprises Limited
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategy

8.7 Lonza Group AG
8.7.1 Business Overview
8.7.2 Operating Segments
8.7.3 Business Strategy

8.8 Koninklijke DSM N.V. (Royal DSM)
8.8.1 Business Overview
8.8.2 Operating Segments
8.8.3 Business Strategy

8.9 Thermo Fisher Scientific Inc.
8.9.1 Business Overview
8.9.2 Operating Segments
8.9.3 Business Strategy

8.10 Recipharm AB
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Fareva Group
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 Symbiosis Pharmaceutical Services
8.12.1 Business Overview
8.12.2 Business Strategy

List of Figures

Figure 1: Benefits Of Healthcare CMOs
Figure 2: Healthcare CMO Segmentation
Figure 3: Global Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 4: Global Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 5: Global Healthcare CMO Market by Type; 2021 (Percentage, %)
Figure 6: Global Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 7: Global Pharmaceutical CMO Market by Value; 2017-2021 (US$ Billion)
Figure 8: Global Pharmaceutical CMO Market by Value; 2022-2027 (US$ Billion)
Figure 9: Global Pharmaceutical CMO Market by Service; 2021 (Percentage, %)
Figure 10: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2017-2021 (US$ Billion)
Figure 11: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2022-2027 (US$ Billion)
Figure 12: Global Other Pharmaceuticals CMO Market by Value; 2017-2021 (US$ Billion)
Figure 13: Global Other Pharmaceuticals CMO Market by Value; 2022-2027 (US$ Billion)
Figure 14: Global Medical Devices CMO Market by Value; 2017-2021 (US$ Billion)
Figure 15: Global Medical Devices CMO Market by Value; 2022-2027 (US$ Billion)
Figure 16: North America Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 17: North America Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 18: North America Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 19: The US Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 20: The US Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 21: The US Healthcare CMO Market by Type; 2021 (Percentage, %)
Figure 22: The US Pharmaceutical Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 23: The US Pharmaceutical Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 24: The US Medical Devices Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 25: The US Medical Devices Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 26: Canada Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 27: Canada Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 28: Mexico Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 29: Mexico Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 30: Europe Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 31: Europe Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 32: Europe Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 33: Germany Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 34: Germany Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 35: The UK Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 36: The UK Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 37: France Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 38: France Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 39: Italy Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 40: Italy Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 41: Spain Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 42: Spain Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 43: Rest of Europe Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 44: Rest of Europe Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 45: Asia Pacific Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 46: Asia Pacific Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 47: Asia Pacific Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 48: China Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 49: China Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 50: Japan Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 51: Japan Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 52: India Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 53: India Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 54: South Korea Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 55: South Korea Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 56: Rest of Asia Pacific Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 57: Rest of Asia Pacific Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 58: Rest of World Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 59: Rest of World Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 60: Global Population Proportion Above 65 Years of Age; 2019 & 2030 (Million)
Figure 61: Global Healthcare Expenditure; 2017 & 2022 (US$ Trillion)
Figure 62: Global Chronic Disease Growth; 2016-2025 (Percentage, %)
Figure 63: Global Generic Drugs Market Value, 2020-2025 (US$ Billion)
Figure 64: Global Natural And Organic Cosmetics And Personal Care Market Value, 2021-2027 (US$ Billion)
Figure 65: Global Healthcare Artificial Intelligence Market Value; 2020-2025 (US$ Billion)
Figure 66: The Global Healthcare CMO Market Players by Research & Development (R&D) Expenses; 2020 & 2021 (US$ Million)
Figure 67: Catalent, Inc. Net Revenue by Segments; 2021 (Percentage, %)
Figure 68: Samsung Biologics Co. Ltd. Revenue by Product Type; 2021 (Percentage, %)
Figure 69: Aurobindo Pharma Limited Revenue by Business Segments; 2021 (Percentage, %)
Figure 70: Boehringher Ingelheim Net Sales by Segments; 2021 (Percentage, %)
Figure 71: Integer Holdings Corporation Net Sales by Segments; 2021 (Percentage, %)
Figure 72: Piramal Enterprises Limited Net Sales by Business; 2021 (Percentage, %)
Figure 73: Lonza Group AG Sales by Segments; 2021 (Percentage, %)
Figure 74: Koninklijke DSM N.V. Net Sales by Business Segments; 2021 (Percentage, %)
Figure 75: Thermo Fisher Scientific Inc. Revenues by Segments; 2021 (Percentage, %)
Table 1: Contracts Placed with Pharmaceutical CDMOs; 2020
Table 2: Global Healthcare CMO Market Players Financial Comparison; 2021



 

ページTOPに戻る


 

Summary

The global healthcare CMO market was valued at US$115.90 billion in 2021, and is predicted to grow to US$230.24 billion in 2027. Healthcare CMOs, or healthcare contract manufacturing organizations, are companies that provide comprehensive services such as drug development and manufacturing for a set period of time under a legal contract.

In the healthcare industry, a Contract Manufacturing Organization (CMO) provides services to pharmaceutical companies, hospitals, and others. Pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, and late-stage clinical trial materials are among the services provided. The global healthcare CMO market is determined to grow at a CAGR of 12.12% over the forecasted period of 2022-2027.

Market Segmentation Analysis:

By Type: The report identifies two segments on the basis of type: Pharmaceutical and Medical Device. Pharmaceutical CMO segment is further divided into two segment on the basis of service: Active Pharmaceutical Ingredients (API) and Others. The device manufacturing segment is expected to grow at the fastest rate in the market during the forecast period, with a CAGR of 13%, owing to increasing outsourcing of device manufacturing due to a lack of in-house manufacturing facilities and complexity. CMOs have quality management systems, assembly, integration and testing capabilities besides supply chain management, experienced manufacturers have systems in place to quickly partner with health care organizations during the fotrecasted period.

By Region: In the report, the global healthcare CMO market is divided into four regions: North America, Europe, Asia Pacific, and ROW. North America accounted for the maximum share of more than 37% of the global market in 2021. The market in North America is being driven by the region’s increased emphasis on drug discovery and manufacturing outsourcing. The region is increasing its use of scientific exploration of disease mechanisms leading to the discovery and development of agents. Pre-clinical testing is an important stage in pharmaceutical research. At this stage, several tests are performed to determine whether a drug is ready for clinical trials.

Asia Pacific is predicted to grow at a significantly high rate during the forecasted period. The governments in various countries in this region are placing large contracts with local CMOs to speed up the production of life supporting devices like ventilators to counter the COVID-19 pandemic. Medical devices like ventilator therefore become more important for providing life support to patients. Therefore, collaboration of authorities with CMOs would lead to increase in production of ventilators, this would bolster the growth of the market during the forecasted years.

Market Dynamics:

Growth Drivers: One of the key drivers of the market's expansion is the growing inclination towards herbal products. Consumers have recently expressed a strong preference for natural/herbal beauty products, so herbal ingredients are increasingly being used in cosmetics and personal care products. In addition, companies are putting more effort into switching from synthetic chemicals to natural ingredients, primarily in response to growing consumer demand and in an effort to find a sustainable source of raw materials. To meet this ongoing demand, organizations are shifting their manufacturing processes to third-party CMOs, which aids in the growth of CMOs in the cosmetics and personal care sector, thus boosting the market growth. Other significant growth factors of the market include, surging geriatric population, rising healthcare expenditure, increasing spread of chronic diseases, escalating demand for generic drugs, and increasing demand for API.

Challenges: However, some challenges are impeding the growth of the market such as rapid technological advancement and dependent on patents, copyrights, trademarks and trade secrets. Industry players rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect many of company’s offerings and intangible assets. These proprietary rights are important to the ongoing operations. The company’s exclusive rights under certain of the offerings are protected by patents, some of which would expire in the near term. When patents covering an offering expire, loss of exclusivity may occur, which may force companies to compete with third parties, thereby negatively affecting the revenue and profitability and simultaneously hinders the growth of the industry.

Trends: The market is projected to grow at a fast pace during the forecast period, due to escalating role of artificial intelligence technology and evolution of advanced respiratory equipment. Healthcare artificial intelligence (AI) has transformed by assisting in repetitive tasks, designing treatment plans, medication management, and drug discovery. It can also be effectively used for healthcare data management by collecting, storing, and normalizing the data. Contract manufacturers are incorporating AI and other technological innovations to become more cost-effective and speed up production time. In addition, pharmaceutical CMOs are constantly developing AI technology in order to facilitate better risk detection and, in turn, improve the quality and safety of pharmaceutical products.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic has become a major public health concern around the world. However, the market experienced a positive demand shock, attributable to the increasing number of biopharmaceutical services provided to CMOs. CMOs have been investing in and acquiring facilities in order to be ready for high-volume production units. This pandemic has proven to be an era of exponential growth in facility and bioprocessing units to have a higher output for increased and continuous supply.

Vaccine development and manufacturing activity in the healthcare CMO market has increased in the last year, owing primarily to the industry's response to the COVID-19 pandemic. This expansion is expected to continue in the coming years as well. CMOs have made capacity and resource investments to address supply chain challenges. The CMO industry has seen an increase in modular construction and expansion, investments in cutting-edge technology, and process intensification strategies. Furthermore, many CMOs are expanding their capabilities in new modalities such as [messenger RNA] mRNA and cell and gene therapy, which would drive the growth of the market during the post COVID period.

Competitive Landscape:

Global healthcare CMO market is moderately consolidated. Strategic collaborations are another common strategy used to gain a competitive advantage. For example, Catalent entered into an agreement with Zumutor Biologics Inc., in February 2020, to produce Zumutor's ZM008 to treat solid tumours.

The key players in the global healthcare CMO market are:

Catalent Pharma Solutions, Inc.
Samsung Biologics Co. Ltd.
Aurobindo Pharma Limited
Boehringer Ingelheim GmbH
Integer Holdings Corporation
Piramal Enterprises Limited
Lonza Group AG
Koninklijke DSM N.V. (Royal DSM)
Thermo Fisher Scientific Inc.
Recipharm AB
Fareva Group
Symbiosis Pharmaceutical Services

The key players in the healthcare CMO market provides a detailed competitive landscape and focus on launching novel products with the necessary approvals. There is a continuing need for research and development, which is still a key strategy among market players. These major players have been implementing novel strategies to expand market prospects in the coming years. In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., global provider of pharmaceutical manufacturing and clinical research services to the biotech industry. This would improve the company's market position by increasing their manufacturing capacity and customer base. In May 2021, Samsung Biologics and Moderna Inc. announced a collaboration to provide fill and finish services for Moderna's COVID-19 Vaccine.



ページTOPに戻る


Table of Contents

1. Executive Summary

2. Introduction

2.1 Healthcare Contract Manufacturing Organization (CMO): An Overview
2.1.1 Benefits Of Healthcare CMOs

2.2 Healthcare CMO Segmentation: An Overview
2.2.1 Healthcare CMO Segmentation

3. Global Market Analysis

3.1 Global Healthcare Contract Manufacturing Organization (CMO) Market: An Analysis

3.1.1 Global Healthcare CMO Market: An Overview
3.1.2 Global Healthcare Contract Manufacturing Organization (CMO) Market by Value
3.1.3 Global Healthcare Contract Manufacturing Organization (CMO) Market by Type (Pharmaceutical and Medical Device)
3.1.4 Global Healthcare Contract Manufacturing Organization (CMO) Market by Region (North America, Europe, Asia Pacific, and rest of the World (ROW)

3.2 Global Healthcare CMO Market: Type Analysis

3.2.1 Global Healthcare CMO Market by Type: An Overview
3.2.2 Global Pharmaceutical CMO Market by Value
3.2.3 Global Pharmaceutical CMO Market by Service (Active Pharmaceutical Ingredients (API) and Others)
3.2.3 Global Pharmaceutical CMO Market by Service: An Overview
3.2.4 Global Active Pharmaceutical Ingredients (API) CMO Market by Value
3.2.5 Global Other Pharmaceuticals CMO Market by Value
3.2.6 Global Medical Devices CMO Market by Value

4. Regional Market Analysis

4.1 North America Healthcare CMO Market: An Analysis

4.1.1 North America Healthcare CMO Market: An Overview
4.1.2 North America Healthcare CMO Market by Value
4.1.3 North America Healthcare CMO Market by Region (The US, Canada and Mexico)
4.1.4 The US Healthcare CMO Market by Value
4.1.5 The US Healthcare CMO Market by Type (Pharmaceutical and Medical Device)
4.1.6 The US Pharmaceutical Healthcare CMO Market by Value
4.1.7 The US Medical Devices Healthcare CMO Market by Value
4.1.8 Canada Healthcare CMO Market by Value
4.1.9 Mexico Healthcare CMO Market by Value

4.2 Europe Healthcare CMO Market: An Analysis

4.2.1 Europe Healthcare CMO Market: An Overview
4.2.2 Europe Healthcare CMO Market by Value
4.2.3 Europe Healthcare CMO Market by Region (Germany, The UK, France, Italy, Spain, and Rest of the Europe)
4.2.4 Germany Healthcare CMO Market by Value
4.2.5 The UK Healthcare CMO Market by Value
4.2.6 France Healthcare CMO Market by Value
4.2.7 Italy Healthcare CMO Market by Value
4.2.8 Spain Healthcare CMO Market by Value
4.2.9 Rest of Europe Healthcare CMO Market by Value

4.3 Asia Pacific Healthcare CMO Market: An Analysis

4.3.1 Asia Pacific Healthcare CMO Market: An Overview
4.3.2 Asia Pacific Healthcare CMO Market by Value
4.3.3 Asia Pacific Healthcare CMO Market by Region (China, Japan, India, South Korea, and Rest of the Asia Pacific)
4.3.4 China Healthcare CMO Market by Value
4.3.5 Japan Healthcare CMO Market by Value
4.3.6 India Healthcare CMO Market by Value
4.3.7 South Korea Healthcare CMO Market by Value
4.3.8 Rest of Asia Pacific Healthcare CMO Market by Value

4.4 Rest of World Healthcare CMO Market: An Analysis

4.4.1 Rest of World Healthcare CMO Market: An Overview
4.4.2 Rest of World Healthcare CMO Market by Value

5. Impact of Covid-19

5.1 Surge in Contracts to CDMOs
5.2 Supply Chain Issues Amidst Surge in Demand for CDMOs
5.3 Preparedness Measures in the Event of Supply Chain Disruption
5.4 Post-COVID Scenario

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Surging Geriatric Population
6.1.2 Rising Healthcare Expenditure
6.1.3 Increasing Spread of Chronic Diseases
6.1.4 Escalating Demand for Generic Drugs
6.1.5 Growing Inclination Towards Herbal Products
6.1.6 Increasing Demand for Active Pharmaceutical Ingredient (API)

6.2 Challenges
6.2.1 Rapid Technological Advancements
6.2.2 Dependent on Patents, Copyrights, Trademarks and Trade Secrets

6.3 Market Trends
6.3.1 Escalating Role of Artificial Intelligence Technology
6.3.2 Evolution of Advanced Respiratory Equipment

7. Competitive Landscape

7.1 Global Healthcare CMO Market Players Financial Comparison
7.2 Global Healthcare CMO Market Players by Research & Development (R&D) Expenses

8. Company Profiles

8.1 Catalent Pharma Solutions Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategy

8.2 Samsung Biologics Co. Ltd.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategy

8.3 Aurobindo Pharma Limited
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategy

8.4 Boehringher Ingelheim
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategy

8.5 Integer Holdings Corporation
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy

8.6 Piramal Enterprises Limited
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategy

8.7 Lonza Group AG
8.7.1 Business Overview
8.7.2 Operating Segments
8.7.3 Business Strategy

8.8 Koninklijke DSM N.V. (Royal DSM)
8.8.1 Business Overview
8.8.2 Operating Segments
8.8.3 Business Strategy

8.9 Thermo Fisher Scientific Inc.
8.9.1 Business Overview
8.9.2 Operating Segments
8.9.3 Business Strategy

8.10 Recipharm AB
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Fareva Group
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 Symbiosis Pharmaceutical Services
8.12.1 Business Overview
8.12.2 Business Strategy

List of Figures

Figure 1: Benefits Of Healthcare CMOs
Figure 2: Healthcare CMO Segmentation
Figure 3: Global Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 4: Global Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 5: Global Healthcare CMO Market by Type; 2021 (Percentage, %)
Figure 6: Global Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 7: Global Pharmaceutical CMO Market by Value; 2017-2021 (US$ Billion)
Figure 8: Global Pharmaceutical CMO Market by Value; 2022-2027 (US$ Billion)
Figure 9: Global Pharmaceutical CMO Market by Service; 2021 (Percentage, %)
Figure 10: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2017-2021 (US$ Billion)
Figure 11: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2022-2027 (US$ Billion)
Figure 12: Global Other Pharmaceuticals CMO Market by Value; 2017-2021 (US$ Billion)
Figure 13: Global Other Pharmaceuticals CMO Market by Value; 2022-2027 (US$ Billion)
Figure 14: Global Medical Devices CMO Market by Value; 2017-2021 (US$ Billion)
Figure 15: Global Medical Devices CMO Market by Value; 2022-2027 (US$ Billion)
Figure 16: North America Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 17: North America Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 18: North America Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 19: The US Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 20: The US Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 21: The US Healthcare CMO Market by Type; 2021 (Percentage, %)
Figure 22: The US Pharmaceutical Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 23: The US Pharmaceutical Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 24: The US Medical Devices Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 25: The US Medical Devices Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 26: Canada Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 27: Canada Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 28: Mexico Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 29: Mexico Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 30: Europe Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 31: Europe Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 32: Europe Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 33: Germany Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 34: Germany Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 35: The UK Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 36: The UK Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 37: France Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 38: France Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 39: Italy Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 40: Italy Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 41: Spain Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 42: Spain Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 43: Rest of Europe Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 44: Rest of Europe Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 45: Asia Pacific Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 46: Asia Pacific Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 47: Asia Pacific Healthcare CMO Market by Region; 2021 (Percentage, %)
Figure 48: China Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 49: China Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 50: Japan Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 51: Japan Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 52: India Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 53: India Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 54: South Korea Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 55: South Korea Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 56: Rest of Asia Pacific Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 57: Rest of Asia Pacific Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 58: Rest of World Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
Figure 59: Rest of World Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
Figure 60: Global Population Proportion Above 65 Years of Age; 2019 & 2030 (Million)
Figure 61: Global Healthcare Expenditure; 2017 & 2022 (US$ Trillion)
Figure 62: Global Chronic Disease Growth; 2016-2025 (Percentage, %)
Figure 63: Global Generic Drugs Market Value, 2020-2025 (US$ Billion)
Figure 64: Global Natural And Organic Cosmetics And Personal Care Market Value, 2021-2027 (US$ Billion)
Figure 65: Global Healthcare Artificial Intelligence Market Value; 2020-2025 (US$ Billion)
Figure 66: The Global Healthcare CMO Market Players by Research & Development (R&D) Expenses; 2020 & 2021 (US$ Million)
Figure 67: Catalent, Inc. Net Revenue by Segments; 2021 (Percentage, %)
Figure 68: Samsung Biologics Co. Ltd. Revenue by Product Type; 2021 (Percentage, %)
Figure 69: Aurobindo Pharma Limited Revenue by Business Segments; 2021 (Percentage, %)
Figure 70: Boehringher Ingelheim Net Sales by Segments; 2021 (Percentage, %)
Figure 71: Integer Holdings Corporation Net Sales by Segments; 2021 (Percentage, %)
Figure 72: Piramal Enterprises Limited Net Sales by Business; 2021 (Percentage, %)
Figure 73: Lonza Group AG Sales by Segments; 2021 (Percentage, %)
Figure 74: Koninklijke DSM N.V. Net Sales by Business Segments; 2021 (Percentage, %)
Figure 75: Thermo Fisher Scientific Inc. Revenues by Segments; 2021 (Percentage, %)
Table 1: Contracts Placed with Pharmaceutical CDMOs; 2020
Table 2: Global Healthcare CMO Market Players Financial Comparison; 2021



 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(プライマリケア)の最新刊レポート

Daedal Research社のプライマリケア分野での最新刊レポート


よくあるご質問


Daedal Research社はどのような調査会社ですか?


デダルリサーチ (Daedal Research) はインドとアジアを始めとして世界の医療や医薬、ICT、エネルギー、通信、化学、交通、消費財などの様々な市場を調査対象とした市場調査報告書を出版してい... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る